Posters to be presented at the AD/PD™ 2024 Conference CHICAGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, which will be held in Lisbon, Portugal and virtually from March 5-9.

2024年2月27日，芝加哥（环球通讯社）——Vanqua Bio今天宣布，该公司将参加AD/PD™2024阿尔茨海默病和帕金森病及相关神经系统疾病国际会议，该会议将于3月5日至9日在葡萄牙里斯本举行。

“We created Vanqua Bio with the aim of developing innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including GBA-PD, which is the largest genetically defined subset of Parkinson’s disease,” said Jim Sullivan, PhD, Co-founder and Chief Executive Officer of Vanqua Bio.

“我们创建Vanqua Bio的目的是开发能够有效减缓或阻止神经退行性疾病进展的创新疗法，包括GBA-PD，它是帕金森病最大的基因定义子集，”Vanqua Bio联合创始人兼首席执行官吉姆·沙利文博士说。

“We look forward to discussing the pre-clinical characterization of our clinical stage program, VQ-101, a brain-penetrant small molecule allosteric activator of GCase. Furthermore, we look forward to sharing data on the development of a live cell GCase activity assay, which has enabled measurement of GCase activation in our preclinical systems and will be used to assess GCase activation in our Phase 1 trial.” Poster presentations: Title: VQ-101, A Small Molecule Allosteric Activator of Glucocerebrosidase, Demonstrates Neuroprotection in Models of GBA-Parkinson’s Disease and Robust In-Vivo Target Engagement Date and time: March 8-9Presenter: Daniel Ysselstein Title: Development and Testing of a Glucocerebrosidase Activity Assay to Evaluate Target Engagement of Allosteric GCase Activators in Whole Blood Samples Date and time: March 8-9Presenter: Daniel Ysselstein About Vanqua BioFounded in 2019 and headquartered in Chicago, Vanqua Bio is a biopharmaceutical company dedicated to discovering and developing next-generation medicines that have the potential to transform the lives of patients with neurodegenera.

“我们期待着讨论我们的临床阶段计划VQ-101的临床前表征，VQ-101是GCase的一种脑渗透性小分子变构激活剂。此外，我们期待着分享有关活细胞GCase活性测定开发的数据，该方法能够在我们的临床前系统中测量GCase活化，并将用于评估我们的GCase活化第一阶段试验。”海报介绍：标题：VQ-101，一种葡萄糖脑苷脂酶的小分子变构激活剂，在GBA帕金森氏病模型中证明了神经保护作用，并在体内实现了强大的目标参与日期和时间：3月8日至9日主持人：Daniel Ysselstein标题：开发和测试葡萄糖脑苷脂酶活性测定法，以评估变构GCase激活剂在全血样本中的目标参与日期和时间：3月8日至9日主持人：Daniel Ysselstein关于2019年Vanqua BioFoundedVanqua Bio总部位于芝加哥，是一家生物制药公司，致力于发现和开发下一代药物，这些药物有可能改变神经退行性疾病患者的生活。